Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Exclusion Criteria

• •Prior treatment:
• •* Must have completed standard radiotherapy and concomitant TMZ therapy as defined and determined by the study oncologist
• •* Besides concomitant TMZ with radiation, no other therapy (neo-adjuvant or adjuvant) can be given prior to study registration, including chemotherapy (also including Gliadel/carmustine \[BCNU\] wafers), biologics, immunotherapy, radiation therapy; the only exception is the Optune device (NovoTTF-100A), which may be started any time after end of radiation therapy up through the initiation of Cycle 1; intent to use Optune must be declared at registration for stratification
• •* No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation
• •Not pregnant and not nursing; females of childbearing potential must have negative urine or serum pregnancy test within 7 days of registration but before start of treatment; a female of childbearing potential is a sexually mature female who:
• •* Has not undergone a hysterectomy or bilateral oophorectomy; or
• •* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
• •Concomitant medications: patients receiving anticoagulation should be on stable dose 2 weeks prior to registration
• •Comorbid conditions: patients are unable to participate due to the following:
• •* Generalized or partial seizure disorder that is uncontrolled at the time of registration; the definition of controlled generalized seizures is patients must be on a stable dose of anti-seizure medication and without generalized seizures for at least 10 days prior to registration; the definition of controlled partial seizures is patients must be on a stable dose of anti-seizure medication for at least 10 days prior to registration; patients with occasional breakthrough partial seizures are allowed at treating physician's discretion
• •* Grade 3 or 4 thromboembolic disease within 6 months (mo) of registration
• •* Known history of prolonged QT syndrome
• •No history of major surgery =\< 14 days prior to registration
• •Patients must have adequate organ and marrow function measured within 28 days prior to administration of ABT-888 as defined below:
• •* \>= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days
• •No Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS